Want to see TSE:NEVI full AI Analyst Report?
NEVI Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.10
Previous CloseN/A
Volume20.00K
Average Volume (3M)55.49K
Market Cap
C$991.57K
Enterprise ValueC$1.32
Total Cash (Recent Filing)C$102.17K
Total Debt (Recent Filing)C$244.21K
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Oct 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume84,932
30 Day Avg. Volume55,489
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthRevenue growth acceleration in 2025 demonstrates that the business is scaling demand and gaining traction. Sustained top-line growth supports operating leverage, reduces relative fixed-cost burden, and creates a clearer path to sustainable profitability if maintained over coming quarters.
Improving Cash GenerationThe shift to positive operating and free cash flow indicates improving cash conversion and discipline. Even though the absolute amount is modest, consistent positive cash generation reduces near-term refinancing risk and underpins reinvestment capability if the trend persists.
Reducing LeverageDeclining debt-to-equity reflects improving balance sheet flexibility and lower financial risk. Reduced leverage diminishes interest burden and enhances capacity to fund operations or strategic initiatives internally, strengthening resilience during execution of growth plans.
Bears Say
Sharp Gross Margin CompressionA dramatic drop in gross margin signals meaningful cost, pricing, or mix deterioration that impairs core profitability. If structural rather than one-off, this erosion undermines operating leverage, forces tighter cost controls, and makes durable margin recovery harder over the medium term.
Ongoing Net Losses And Negative MarginsDespite improvement, persistent net losses and materially negative margins mean the company still consumes equity and faces capital pressure. Sustained profitability is required to stop equity erosion and produce returns; continued negative margins raise risk of future financing needs.
Modest Cash Generation Vs Historical VolatilityPositive FCF in 2025 is encouraging but small and follows volatile prior years. The modest scale relative to losses and historical cash instability implies funding risk if improvements stall, leaving the firm exposed to external capital needs or constrained reinvestment ability.
Pascal Biosciences Inc News
NEVI FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.02 and its highest was C$0.10 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is C$991.57K.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Oct 16, 2026 which is in 72 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Pascal Biosciences Inc released its earnings results on Jul 16, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Pascal Biosciences Inc reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:NEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
West Island Brands Inc
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―